Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy.
Khorana Risk Score (KRS)
chemotherapy
deep vein thrombosis (DVT)
primary central nervous system lymphoma (PCNSL)
pulmonary embolism
venous thromboembolism (VTE)
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
22
01
2020
revised:
08
06
2020
accepted:
20
06
2020
entrez:
1
9
2020
pubmed:
31
8
2020
medline:
31
8
2020
Statut:
epublish
Résumé
In primary central nervous system lymphoma (PCNSL), venous thromboembolism (VTE) can cause significant morbidity and hinder chemotherapy delivery. To assess VTE incidence, timing and adequacy of inpatient and outpatient VTE prophylaxis in patients with PCNSL receiving chemoimmunotherapy with curative intent. We reviewed patients diagnosed with PCNSL between 1997 and 2018 who received methotrexate, procarbazine, and vincristine ± Rituximab. Patient demographics, VTE prophylaxis and incidence, adverse events of anticoagulation, and survival outcomes were collected. Fifty-one PCNSL patients were included (median 67 years [range, 32-87], 30 males [59%]). Thirteen patients (25%, 95% confidence interval [CI], 14-40) developed VTE at a median of 1.6 months from diagnosis (range, 0-4). Patients with Khorana Risk Score ≥2 were more likely to have VTE than those with a KRS < 2 (60% vs 15%; Patients with newly diagnosed PCNSL are at high risk of VTE. Further research is required into optimal VTE prophylaxis in PCNSL.
Sections du résumé
BACKGROUND
BACKGROUND
In primary central nervous system lymphoma (PCNSL), venous thromboembolism (VTE) can cause significant morbidity and hinder chemotherapy delivery.
OBJECTIVES
OBJECTIVE
To assess VTE incidence, timing and adequacy of inpatient and outpatient VTE prophylaxis in patients with PCNSL receiving chemoimmunotherapy with curative intent.
PATIENTS/METHODS
METHODS
We reviewed patients diagnosed with PCNSL between 1997 and 2018 who received methotrexate, procarbazine, and vincristine ± Rituximab. Patient demographics, VTE prophylaxis and incidence, adverse events of anticoagulation, and survival outcomes were collected.
RESULTS
RESULTS
Fifty-one PCNSL patients were included (median 67 years [range, 32-87], 30 males [59%]). Thirteen patients (25%, 95% confidence interval [CI], 14-40) developed VTE at a median of 1.6 months from diagnosis (range, 0-4). Patients with Khorana Risk Score ≥2 were more likely to have VTE than those with a KRS < 2 (60% vs 15%;
CONCLUSIONS
CONCLUSIONS
Patients with newly diagnosed PCNSL are at high risk of VTE. Further research is required into optimal VTE prophylaxis in PCNSL.
Identifiants
pubmed: 32864550
doi: 10.1002/rth2.12415
pii: S2475-0379(22)02075-1
pmc: PMC7443429
doi:
Types de publication
Journal Article
Langues
eng
Pagination
997-1003Informations de copyright
© 2020 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
Références
J Clin Oncol. 2003 Jan 15;21(2):266-72
pubmed: 12525518
Medicine (Baltimore). 2019 Nov;98(47):e17894
pubmed: 31764785
Chest. 2016 Feb;149(2):315-352
pubmed: 26867832
Neuro Oncol. 2008 Aug;10(4):560-8
pubmed: 18559969
Neurology. 2002 May 28;58(10):1513-20
pubmed: 12034789
J Thromb Haemost. 2005 Aug;3(8):1611-7
pubmed: 16102026
Thromb Res. 2010 Apr;125 Suppl 2:S58-61
pubmed: 20434007
J Natl Compr Canc Netw. 2013 Nov;11(11):1402-29
pubmed: 24225973
Curr Opin Pulm Med. 2001 Sep;7(5):326-31
pubmed: 11584184
Lancet Haematol. 2016 May;3(5):e217-27
pubmed: 27132696
J Thromb Haemost. 2015 Nov;13(11):2119-26
pubmed: 26764429
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354
Blood. 2008 May 15;111(10):4902-7
pubmed: 18216292
Lancet. 2013 Jul 27;382(9889):311-25
pubmed: 23697825
J Clin Oncol. 2007 Oct 20;25(30):4730-5
pubmed: 17947720
Br J Cancer. 2011 Oct 25;105(9):1414-8
pubmed: 21915121
Neurology. 2005 Jan 11;64(1):69-74
pubmed: 15642906
N Engl J Med. 2000 Dec 21;343(25):1846-50
pubmed: 11117976
Cochrane Database Syst Rev. 2018 Jun 01;6:CD006468
pubmed: 29856471
Thromb Res. 2016 Jul;143:86-90
pubmed: 27208462
N Engl J Med. 2019 Feb 21;380(8):711-719
pubmed: 30511879
Thromb Res. 2014 May;133 Suppl 2:S23-8
pubmed: 24862141
Rheumatology (Oxford). 2002 Jun;41(6):658-65
pubmed: 12048292
Am Surg. 2015 Jul;81(7):732-7
pubmed: 26140896
J Clin Oncol. 2013 Nov 1;31(31):3971-9
pubmed: 24101038
Arch Intern Med. 2006 Feb 27;166(4):458-64
pubmed: 16505267
Blood. 2003 Jan 15;101(2):466-8
pubmed: 12393404
J Thromb Haemost. 2013 Jan;11(1):71-80
pubmed: 23217208
Thromb Haemost. 2017 Apr 27;:
pubmed: 28447710
Cancer. 2003 Sep 15;98(6):1239-42
pubmed: 12973848
Ann Oncol. 2015 Sep;26 Suppl 5:v152-68
pubmed: 26314776
J Thromb Haemost. 2010 Nov;8(11):2483-93
pubmed: 20735729